Description 
FIND‑CKD (NCT05047263) was a randomized, double‑blind, placebo‑controlled trial of finerenone in chronic kidney disease (September 2021–February 2026) that contributed to a participant‑level pooled analysis published in The Lancet. The pooled cohort (FIDELIO‑DKD, FIGARO‑DKD, FIND‑CKD) included 14,574 participants (mean age 63.7 years, 30.7% female, mean eGFR 56.4 mL/min/1.73 m², median UACR 567.4 mg/g) and specifically extends evidence for finerenone into non‑diabetic CKD. Finerenone reduced the composite kidney outcome (kidney failure or sustained ≥57% eGFR decline) by 24% (HR 0.76) and lowered the composite cardiovascular outcome (heart‑failure hospitalization or cardiovascular death) by 20% (HR 0.80); heart‑failure hospitalization and all‑cause death were also reduced. Importantly, kidney benefit was consistent irrespective of glycaemic status, CKD aetiology, baseline eGFR, albuminuria, and SGLT2‑inhibitor use—supporting finerenone for albuminuric non‑diabetic CKD when potassium monitoring is available. These results broaden finerenone’s evidence base and support guideline positioning of nonsteroidal MRAs as add‑on therapy for persistent albuminuria.